Effect of Growth Hormone in Children With Growth Hormone Deficiency
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
This trial is conducted in the United States of America (USA). The purpose of the trial is to compare the effect of Norditropin® using different dosing regimens in children suspected of growth hormone deficiency.
Condition or disease
Growth Hormone DisorderGrowth Hormone Deficiency in ChildrenGrowth DisorderIdiopathic Short Stature
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Layout table for eligibility information
Ages Eligible for Study:
3 Years to 15 Years (Child)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Clinically suspected GHD
Height < -2.0 SDS
Serum IGF-I less than or equal to -1.0 SDS
Bone age less than or equal to 9 years for boys and less than or equal to 7 years for girls.
Puberty Tanner Stage I
Previous use of growth hormone
Growth retardation attributable to causes other than GHD (e.g. inborn errors of metabolism, primary bone disease, chromosomal disorders, etc.)